[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

Autor: E. J. van Helden, E.G.E. de Vries, Sjoerd G. Elias, N.C.T. van Grieken, C.M.L. van Herpen, S. C. van Es, D.J. Vugts, Ronald Boellaard, C. W. Menke-van der Houven van Oordt, Wim J.G. Oyen, H. M. W. Verheul, Otto S. Hoekstra, M. C. Huisman, Sophie L. Gerritse, G.A.M.S. (Guus) van Dongen, Eline Boon, Henk L. Dekker, Adrienne H. Brouwers

Publikováno v: European Journal of Nuclear Medicine and Molecular Imaging, 47, 4, pp. 849-859
European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 849-859. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 47, 849-859. SPRINGER
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 47(4), 849. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 47, 849-859
van Helden, E J, Elias, S G, Gerritse, S L, van Es, S C, Boon, E, Huisman, M C, van Grieken, N C T, Dekker, H, van Dongen, G A M S, Vugts, D J, Boellaard, R, van Herpen, C M L, de Vries, E G E, Oyen, W J G, Brouwers, A H, Verheul, H M W, Hoekstra, O S & Menke-van der Houven van Oordt, C W 2020, ' [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. 4, pp. 849-859 . https://doi.org/10.1007/s00259-019-04555-6

Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [89Zr]Zr-cet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649e8819f0b3fb0a2350dc60b8a96a2f
https://hdl.handle.net/2066/219439

Radiomics analysis of pre-treatment [F-18]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

Autor: F. H. P. van Velden, Henk M.W. Verheul, E. J. van Helden, C W Menke-van der Houven van Oordt, Otto S. Hoekstra, Y. J. L. Vacher, Ronald Boellaard, W. N. van Wieringen

Publikováno v: European Journal of Nuclear Medicine and Molecular Imaging, 45(13), 2307-2317. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 45(13), 2307-2317
van Helden, E J, Vacher, Y J L, van Wieringen, W N, van Velden, F H P, Verheul, H M W, Hoekstra, O S, Boellaard, R & Menke-van der Houven van Oordt, C W 2018, ' Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, no. 13, pp. 2307-2317 . https://doi.org/10.1007/s00259-018-4100-6
European Journal of Nuclear Medicine and Molecular Imaging

BACKGROUND: The aim of this study was to assess radiomics features on pre-treatment [18F]FDG positron emission tomography (PET) as potential biomarkers for response and survival in patients with metastatic colorectal cancer (mCRC).METHODS: Patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::636b537ef7fe97d02f418ed8aa561660
https://hdl.handle.net/1887/79158

Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy

Autor: Maurice P.H.M. Jansen, S. C. van Es, E. G. E. de Vries, E. J. van Helden, Stefan Sleijfer, C.M.L. van Herpen, C. W. Menke-van der Houven van Oordt, H. M. W. Verheul, Lindsay Angus, Eline Boon, Derk Jan A. de Groot

Publikováno v: Angus, L, van Helden, E J, van Es, S C, Boon, E, van Herpen, C M L, de Groot, D J, de Vries, E G E, Menke-van der Houven van Oordt, C W, Sleijfer, S, Verheul, H M & Jansen, M P H M 2018, ' Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii50 . https://doi.org/10.1093/annonc/mdy269.156
Annals of oncology : official journal of the European Society for Medical Oncology, 29. Oxford University Press

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985cc8be2fd965567673a7d67a91011d
https://research.vumc.nl/en/publications/4a8e932e-dd9a-4435-a26b-76dfa9aef97d

Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC)

Autor: Sandra Heskamp, Lindsay Angus, C.M.L. van Herpen, A.A.M. Van der Veldt, E.G.E. de Vries, Wim J.G. Oyen, Sarah R. Verhoeff, Otto C. Boerman, Otto S. Hoekstra, W.T.A. van der Graaf, S.G. Elias, Adrienne H. Brouwers, Suzanne C van Es, Henk M.W. Verheul, Erik H.J.G. Aarntzen, Sjoukje F. Oosting, E. J. van Helden, E. Boon

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii314-viii315. Oxford University Press
Annals of Oncology, 29(Suppl.8):888P, viii314-viii315. Oxford University Press
Verhoeff, S R, Es, S, Boon, E, van Helden, E, Angus, L, Elias, S, Oosting, S, Aarntzen, E, Brouwers, A, Heskamp, S, Hoekstra, O S, Verheul, H M, Van der Veldt, A A M, de Vries, E G E, Boerman, O, van der Graaf, W T A, Oyen, W J G & van Herpen, C M L 2018, ' Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii314-viii315 . https://doi.org/10.1093/annonc/mdy283.097

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e8aae6e2db1193b77e5ad53f812cdb7
https://doi.org/10.1093/annonc/mdy283.097